comparemela.com
Home
Live Updates
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance : comparemela.com
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
Fiscal Year 2024 First Quarter Highlights
Net sales of $78.7 million as reported
Includes $0.7 million of Dialysis and BioSentry Biopsy Tract Sealant System sales
Net sales increased 5.7%...
Related Keywords
United States
,
Canada
,
Australia
,
Jim Clemmer
,
European Union
,
Company Dialysis
,
Angiodynamics Inc
,
Drug Administration
,
Nasdaq
,
Fiscal Year
,
Chief Executive Officer
,
Biosentry Tract Sealant System
,
Med Device
,
Med Tech
,
Biosentry Tract Sealant System Biopsy
,
Merit Medical
,
Private Securities Litigation Reform Act
,
Annual Report
,
Nanoknife System
,
Biosentry Businesses
,
Net Income
,
Net Loss
,
Diluted Earnings
,
Per Share
,
Diluted Loss Per Share
,
Pro Forma Net Income
,
Pro Forma Adjusted Net Loss
,
Pro Forma Diluted Earnings
,
Pro Forma Adjusted
,
Stockholder Equity
,
Markets
,
comparemela.com © 2020. All Rights Reserved.